dc.contributor.author | Brand, DH | |
dc.contributor.author | Kirby, AM | |
dc.contributor.author | Yarnold, JR | |
dc.contributor.author | Somaiah, N | |
dc.date.accessioned | 2022-04-19T11:30:24Z | |
dc.date.available | 2022-04-19T11:30:24Z | |
dc.date.issued | 2022-05-01 | |
dc.identifier.citation | Clinical oncology (Royal College of Radiologists (Great Britain)), 2022, 34 (5), pp. 280 - 287 | |
dc.identifier.issn | 0936-6555 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5089 | |
dc.identifier.eissn | 1433-2981 | |
dc.identifier.eissn | 1433-2981 | |
dc.identifier.doi | 10.1016/j.clon.2022.02.009 | |
dc.identifier.doi | 10.1016/j.clon.2022.02.009 | |
dc.description.abstract | Hypofractionated radical radiotherapy is now an accepted standard of care for tumour sites such as prostate and breast cancer. Much research effort is being directed towards more profoundly hypofractionated (ultrahypofractionated) schedules, with some reaching UK standard of care (e.g. adjuvant breast). Hypofractionation exerts varying influences on each of the major clinical end points of radiotherapy studies: acute toxicity, late toxicity and local control. This review will discuss these effects from the viewpoint of the traditional 5 Rs of radiobiology, before considering non-canonical radiobiological effects that may be relevant to ultrahypofractionated radiotherapy. The principles outlined here may assist the reader in their interpretation of the wealth of clinical data presented in the tumour site-specific articles in this special issue. | |
dc.format | Print-Electronic | |
dc.format.extent | 280 - 287 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ELSEVIER SCIENCE LONDON | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Breast | |
dc.subject | Humans | |
dc.subject | Breast Neoplasms | |
dc.subject | Prostatic Neoplasms | |
dc.subject | Treatment Outcome | |
dc.subject | Radiobiology | |
dc.subject | Male | |
dc.subject | Radiation Dose Hypofractionation | |
dc.title | How Low Can You Go? The Radiobiology of Hypofractionation. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2022-02-11 | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1016/j.clon.2022.02.009 | |
dc.relation.isPartOf | Clinical oncology (Royal College of Radiologists (Great Britain)) | |
pubs.issue | 5 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Breast Cancer Radiotherapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Breast Cancer Radiotherapy/Breast Cancer Radiotherapy (hon.) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Stereotactic and Precision Body Radiotherapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Breast Radiobiology | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR/Students | |
pubs.organisational-group | /ICR/Students/PhD and MPhil | |
pubs.organisational-group | /ICR/Students/PhD and MPhil/17/18 Starting Cohort | |
pubs.publication-status | Accepted | |
pubs.volume | 34 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Breast Cancer Radiotherapy | |
icr.researchteam | Stereotactic and Precision Body Radiotherapy | |
icr.researchteam | Translational Breast Radiobiology | |
dc.contributor.icrauthor | Brand, Douglas | |
dc.contributor.icrauthor | Yarnold, John | |
dc.contributor.icrauthor | Somaiah, Navita | |